SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IPIC
IPIC 0.00010000.0%Nov 28 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: WeirdPro Randy who wrote (944)12/19/1997 4:52:00 PM
From: NeuroInvestment  Read Replies (1) of 1359
 
The first study is being run by AHP...it is the remains of what would have been a large Phase III for Redux II, a once-daily formulation. With the Redux crash, drug administration was stopped, but they have 1000 people who they are following for cardio changes. There is supposed to be some data out in January, but it will not have much in the way of duration data, I believe no one received Redux II longer than 2 months or so. It will at least give a comparison to a matched placebo group where other comorbid conditions can be controlled for. The 1200 patient AHP/Harvard study (which we will hear about in April most likely) will contrast Redux with fen-phen and placebo retrospectively....I am sure they will look at duration, dose, and comorbid conditions, and I am sure both studies will break down any valvular pathology by type and extent. The 1200 pt study will be more important, because it will give us a look at duration, which I think will be a key variable. NeuroInvestment
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News